Pan-Solid Tumor RNA Fusion Panel Receives Approval for CMS Reimbursement, Wednesday, July 24, 2024

Beginning Wednesday, July 24th

Pan-Solid Tumor RNA Fusion Panel available in the Molecular Pathology Laboratory at Medical Center University (MCU) has received CMS approval for Medicare reimbursement for all solid tumors. This determination is retroactive to the original submission date of June 18, 2024.

This 153-gene panel combines and expands the existing RNA fusion assays by including all targets present in Lung Gene RNA Fusion Panel (LAB8567), Tumor Gene RNA Fusion Profile (LAB8956), Sarcoma Fusion Panel (LAB8427), and Salivary Gland Tumor Fusion Panel (LAB8690).

Pan-Solid Tumor RNA Fusion Panel (LAB9492, Z04JV)

Key features:

The panel targets gene rearrangements of these genes: ACVR2A, AKT1, AKT2, AKT3, ALK, AR, ARHGAP26, ARHGAP6, ATF1, AXL, BCOR, BEND2, BRAF, BRD3, BRD4, C11orf95, CALCA, CAMTA1, CCNB3, CCND1, CD274, CIC, CREB1, CREM, CRTC1, CSF1, CSF1R, CTNNB1, DDR2, DNAJB1, EGF, EGFR, EPC1, ERBB2, ERBB4, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGF1, FGFR1, FGFR2, FGFR3, FGR, FOS, FOSB, FOXO1, FOXO4, FOXR2, FUS, GLI1, GNAS, GRB7, HMGA2, HRAS, IDH1, IDH2, IGF1R, INSR, JAK2, JAK3, JAZF1, KIT, KRAS, KRT20, KRT7, MAML2, MAP2K1, MAST1, MAST2, MBTD1, MDM2, MEAF6, MERTK, MET, MGEA5, MKL2, MN1, MSMB, MUSK, MYB, MYBL1, MYC, MYOD1, NCOA1, NCOA2, NCOA3, NFATC2, NFE2L2, NFIB, NOTCH1, NOTCH2, NR4A3, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PAX3, PAX8, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PHKB, PIK3CA, PKN1, PLAG1, PPARG, PRDM10, PRKACA, PRKACB, PRKCA, PRKCB, PRKCD, PRKD1, PRKD2, PRKD3, PTH, RAD51B, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, SLC5A5, SS18, SS18L1, STAT6, TAF15, TCF12, TEK, TERT, TFE3, TFEB, TFG, TGFA, THADA, TMPRSS2, TTF1, USP6, VGLL2, WWTR1, YAP1, YWHAE

For questions, please contact Sarah Hornberg, Molecular Laboratory Supervisor (384-9870, sarah-hornberg@uiowa.edu).